Literature DB >> 7521346

Use of insulin-like growth factor-binding protein-2 (IGFBP-2), IGFBP-3, and IGF-I for assessing growth hormone status in short children.

W J Smith1, T J Nam, L E Underwood, W H Busby, A Celnicker, D R Clemmons.   

Abstract

Insulin-like growth factor-binding protein-2 and -3 (IGFBP-2 and -3) are members of a family of proteins that are present in extracellular fluids and bind IGF-I and -II. IGFBP-2 is regulated differently from IGF-I and IGFBP-3, because its serum concentrations are elevated in some adults with GH deficiency (GHD), whereas IGF-I and IGFBP-3 concentrations are usually decreased. The purposes of this study were to define the normal range of IGFBP-2 concentrations in children, to determine its efficacy in the diagnosis of GHD, and to compare the diagnostic value of measurements of the serum GH response to provocative testing with results of measurements of IGFBP-2, IGFBP-3, and IGF-I. Mean serum IGFBP-2 concentrations ranged from 263 +/- 101 ng/mL (mean +/- SD) during infancy to 136 +/- 38 ng/mL in normal 15- to 18-yr-olds (P < 0.001), whereas IGFBP-3 increased from 1211 +/- 384 to 2781 +/- 382 ng/mL in the same age groups. Thirty-nine of 49 children with GHD and low IGF-I values (serum GH response, < or = 1 ng/mL after 2 provocative tests) had serum IGFBP-2 concentrations that were greater than 2 SD above their corresponding age-adjusted means. In contrast all 49 of these children had IGFBP-3 values that were below normal for age. Because serum IGFBP-2 concentrations are regulated by GH directly and not through IGF-I, the IGFBP-2 to IGF-I ratio was used to determine whether it improved diagnostic accuracy. Fifty of 57 GH-deficient children had IGFBP-2/IGF-I ratios that were greater than 2 SD above the mean. This included 48 of 49 children with low IGF-I and 2 of 8 children with normal IGF-I. Fifty-three of the 57 children with GHD had decreased IGFBP-3 values. Among 23 children with idiopathic short stature (ISS) who had normal responses to GH stimulation testing (serum GH, > 10 ng/mL), 7 had low IGF-I values. Of the 7, all had an increased IGFBP-2/IGF-I ratio and a low IGFBP-3 level. Of the remaining 16 children with normal IGF-I, 13 had a normal IGFBP-2/IGF-I ratio and normal IGFBP-3 values. Three had low IGFBP-3 and an increased IGFBP-2/IGF-I ratio. In 76% of the 80 short-statured patients studied, there was concordance among serum GH responses to provocative tests, IGF-I, IGFBP-2/IGF-I ratio, and IGFBP-3.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7521346     DOI: 10.1210/jcem.77.5.7521346

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

1.  Discovery and validation of serum protein changes in type 1 diabetes patients using high throughput two dimensional liquid chromatography-mass spectrometry and immunoassays.

Authors:  Wenbo Zhi; Ashok Sharma; Sharad Purohit; Eric Miller; Bruce Bode; Stephen W Anderson; John Chip Reed; R Dennis Steed; Leigh Steed; Diane Hopkins; Jin-Xiong She
Journal:  Mol Cell Proteomics       Date:  2011-09-06       Impact factor: 5.911

2.  Is the persistence of isolated GH deficiency in adulthood predicted by anatomical hypothalamic-pituitary alterations?

Authors:  S Vannelli; B Stasiowska; J Bellone; G Aimaretti; S Bellone; T Avataneo; S Cirillo; L Benso
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

3.  The role of insulin like growth factor (IGF)-1 and IGF-binding protein-3 in diagnosis of Growth Hormone Deficiency in short stature children.

Authors:  Zahra Haghshenas; Kambiz Sotoudeh; Hamdollah Karamifar; Zohreh Karamizadeh; Gholamhossein Amirhakimi
Journal:  Indian J Pediatr       Date:  2009-04-16       Impact factor: 1.967

Review 4.  Growth hormone deficiency in children.

Authors:  Erick J Richmond; Alan D Rogol
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

5.  Liver-specific GH receptor gene-disrupted (LiGHRKO) mice have decreased endocrine IGF-I, increased local IGF-I, and altered body size, body composition, and adipokine profiles.

Authors:  Edward O List; Darlene E Berryman; Kevin Funk; Adam Jara; Bruce Kelder; Feiya Wang; Michael B Stout; Xu Zhi; Liou Sun; Thomas A White; Nathan K LeBrasseur; Tamara Pirtskhalava; Tamara Tchkonia; Elizabeth A Jensen; Wenjuan Zhang; Michal M Masternak; James L Kirkland; Richard A Miller; Andrzej Bartke; John J Kopchick
Journal:  Endocrinology       Date:  2014-02-11       Impact factor: 4.736

6.  The effect of GH therapy on the immunoreactive forms and distribution of IGFBP-3, IGF-I, the acid-labile subunit, and growth rate in GH-deficient children.

Authors:  S H Mandel; E Moreland; R G Rosenfeld; S E Gargosky
Journal:  Endocrine       Date:  1997-12       Impact factor: 3.633

7.  Overlap of Peak Growth Activity and Peak IGF-1 to IGFBP Ratio: Delayed Increase of IGFBPs versus IGF-1 in Serum as a Mechanism to Speed up and down Postnatal Weight Gain in Mice.

Authors:  Michael Walz; Luong Chau; Christina Walz; Mandy Sawitzky; Daniela Ohde; Julia Brenmoehl; Armin Tuchscherer; Martina Langhammer; Friedrich Metzger; Christine Höflich; Andreas Hoeflich
Journal:  Cells       Date:  2020-06-22       Impact factor: 6.600

Review 8.  IGF-I assays: current assay methodologies and their limitations.

Authors:  David R Clemmons
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

Review 9.  Utility of free IGF-I measurements.

Authors:  Jan Frystyk
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

10.  Cell non-autonomous regulation of hepatic IGF-1 and neonatal growth by Kinase Suppressor of Ras 2 (KSR2).

Authors:  Lili Guo; Diane L Costanzo-Garvey; Deandra R Smith; Megan E Zavorka; Megan Venable-Kang; Richard G MacDonald; Robert E Lewis
Journal:  Sci Rep       Date:  2016-08-26       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.